Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2020-05-28 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
[기재정정]분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Ilyang Pharmaceutical Co., Ltd. for the 1st quarter of the 50th fiscal year (2020). It contains detailed financial statements, business descriptions, and management analysis, which are characteristic of an Interim/Quarterly Report. Although it mentions a 'correction' (정정신고), the document itself is the full quarterly report filing, not just an announcement of one. Q1 2020
2020-05-28 Korean
[기재정정]분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the 50th fiscal period (1st quarter) of Ilyang Pharmaceutical Co., Ltd. It contains detailed financial statements, management discussion and analysis, and corporate governance information. Although it mentions a 'correction' (정정신고), it is a comprehensive financial report for an interim period, not merely an announcement of a report or a certification letter. Therefore, it falls under the category of Interim / Quarterly Report. Q1 2020
2020-05-28 Korean
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '일양약품(주)' (Ilyang Pharm Co., Ltd.) for the first quarter of 2020 (2020.01.01-2020.03.31). It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement or certification, as it provides comprehensive financial and operational data. Q1 2020
2020-05-15 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for the company Ilyang Pharmaceutical. It details specific transactions (buys and sells) made by individuals identified as major shareholders or their relatives. This type of filing is a standard regulatory requirement for reporting insider transactions and changes in significant shareholdings, which falls under the 'Director's Dealing' category as it tracks personal share transactions by company-affiliated individuals.
2020-04-27 Korean
사업보고서 (2019.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the 49th fiscal year (2019), covering financial statements, business operations, governance, and management analysis. It is a formal, long-form regulatory filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange. Based on the content and structure, it is a standard Annual Report (10-K equivalent in the Korean market). FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (AGM) for Il-Yang Pharmaceutical. It details the outcomes of agenda items such as financial statement approval, dividend declarations, and the election of directors and audit committee members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2020-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.